NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

Janna Heide1, Agnes J Bilecz1, Samarjit Patnaik2

  • 1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.

Nature
|July 23, 2025
PubMed

Insights

Nicotinamide N-methyltransferase (NNMT) fuels cancer by recruiting immunosuppressive cells. Inhibiting NNMT in cancer-associated fibroblasts (CAFs) boosts anti-tumor immunity and reduces tumor growth, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Cancer-associated fibroblasts (CAFs) play a critical role in tumor progression.
  • Targeting CAFs remains a challenge in cancer therapy.

Purpose of the Study:

  • To investigate the role of nicotinamide N-methyltransferase (NNMT) in high-grade serous ovarian cancer.
  • To identify NNMT as a potential therapeutic target for cancer treatment.

Main Methods:

  • Spatial transcriptomics and single-cell RNA sequencing were employed.
  • NNMT's role was assessed in syngeneic mouse models of ovarian, breast, and colon cancer.
  • High-throughput screening was used to identify NNMT inhibitors.

Main Results:

  • NNMT promotes tumor growth by inducing H3K27me3 hypomethylation in CAFs, leading to the secretion of immunosuppressive factors and recruitment of myeloid-derived suppressor cells (MDSCs).
  • NNMT knockout impaired tumor growth and enhanced CD8+ T cell activation in multiple cancer models.
  • A novel NNMT inhibitor reduced tumor burden, metastasis, and restored anti-tumor immunity.

Conclusions:

  • NNMT is a key regulator of CAFs and immunosuppression within the tumor microenvironment.
  • Targeting NNMT represents a promising therapeutic strategy to enhance anti-tumor immunity and overcome treatment resistance.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K